Biomedica Medizinprodukte Gmbh & Co. Kg

Stratec Consumables Gmbh

Fianostics Gmbh

The Antibody Lab Gmbh

Gerhard Hawa

Wolfgang Woloszczuk

Georg Bauer

Adrian Prinz

Christoph Mauracher

Soheyl Bahrami

Gottfried Aichinger

The present invention relates to the use of a substrate for enhancing the fluorescence of a fluorescent molecule, wherein the substrate comprises a solid polymer carrier having a plurality of recesses separated from each other and wherein the solid carrier is coated at least in part by a metal.

Substrate for fluorescence amplification

The invention relates to a method of determining feline or canine proBNP or fragments thereof for the diagnosis of heart disease, comprising the steps of providing a feline or canine sample, contacting the sample with at least one species-specific antibody for binding to at least one epitope of the respective species proBNP, determining the concentration of at least one fragment of proBNP, and diagnosing the animal with heart disease if the concentration is elevated compared to healthy subjects.

Determining feline proBNP

The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample.

Method of determining equine NT-proBNP

Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 68 to 80 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.

The invention relates to a method of determining feline or canine proBNP or fragments thereof, comprising the steps of

Identification of canine proBNP by immunoassay

The invention describes a method for diagnosing of septic complications in polytraumatised human or animal patients, said patients being free of traumatic brain injury, by determining the level of the C-type natriuretic peptide (CNP), its precursors or fragments thereof, especially the precursor of the C-type natriuretic peptide (NT-proCNP), in this patient and diagnosing the patient a having septic complications or being at risk of developing septic complications, if the level of CNP, its precursors or fragments thereof, especially NT-proCNP, is increased compared to normal levels.

Growing community of inventors

Vienna, Austria

Gerhard Hawa